Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Convertible Debt (2020 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Convertible Debt for 6 consecutive years, with $309.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Convertible Debt rose 0.57% year-over-year to $309.6 million, compared with a TTM value of $309.6 million through Sep 2025, up 0.57%, and an annual FY2024 reading of $308.3 million, up 8.15% over the prior year.
  • Convertible Debt was $309.6 million for Q3 2025 at Tandem Diabetes Care, roughly flat from $309.1 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $347.5 million in Q1 2024 and bottomed at $280.2 million in Q1 2021.
  • Average Convertible Debt over 5 years is $294.2 million, with a median of $284.1 million recorded in 2023.
  • The sharpest move saw Convertible Debt soared 43.64% in 2021, then decreased 11.16% in 2025.
  • Year by year, Convertible Debt stood at $281.5 million in 2021, then increased by 0.63% to $283.2 million in 2022, then grew by 0.64% to $285.0 million in 2023, then increased by 8.15% to $308.3 million in 2024, then rose by 0.43% to $309.6 million in 2025.
  • Business Quant data shows Convertible Debt for TNDM at $309.6 million in Q3 2025, $309.1 million in Q2 2025, and $308.7 million in Q1 2025.